© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Minerva Surgical, Inc. (UTRS) stock remained unchanged at $0.00 a share on OTC. The stock opened at $0.00, fluctuating between $0.00 to $0.00 during the session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 19, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 204 |
| Aug 10, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 752 |
| May 20, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 30K |
| May 07, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 999 |
| Apr 23, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1.53K |
| Apr 20, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 516 |
| Apr 06, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 150 |
| Jan 29, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 110 |
| Jan 26, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 255 |
| Jan 15, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 352 |
| Jan 12, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 617 |
| Jan 08, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 209 |
| Jan 02, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 2.67K |
| Dec 30, 2025 | 0.00 | 0.00 | 0.00 | 0.00 | 208 |
| Dec 29, 2025 | 0.00 | 0.00 | 0.00 | 0.00 | 9.32K |
| Dec 26, 2025 | 0.00 | 0.00 | 0.00 | 0.00 | 341 |
| Dec 24, 2025 | 0.00 | 0.00 | 0.00 | 0.00 | 189 |
| Dec 05, 2025 | 0.00 | 0.00 | 0.00 | 0.00 | 1.37K |
| Dec 01, 2025 | 0.00 | 0.00 | 0.00 | 0.00 | 301 |
| Nov 04, 2025 | 0.00 | 0.00 | 0.00 | 0.00 | 110 |
Minerva Surgical, Inc. functions as a commercial-stage medical technology enterprise, specializing in the creation, production, and distribution of innovative, minimally invasive solutions tailored to address the uterine healthcare needs of women throughout the United States. Their suite of offerings features advanced endometrial ablation systems, including the Minerva ES and Genesys HTA. They also provide the Symphion Tissue Removal System, a sophisticated, minimally invasive device for uterine tissue removal that uniquely integrates bladeless tissue resection, coagulation capabilities, continuous visualization during procedures, and precise intrauterine pressure monitoring. Additionally, the Resectr Tissue Resection Device is a handheld surgical tool engineered for the hysteroscopic removal and diagnostic evaluation of endometrial polyps. These specialized instruments are utilized by obstetrician-gynecologists across a variety of clinical settings, such as hospitals, outpatient ambulatory surgical centers, and private physician practices. The company was founded in 2008 and is headquartered in Santa Clara, California.
| Employees | 174 |
| Beta | 4.6 |
| Sales or Revenue | $50.29M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |